Skip to content
Brand AI

China Resources Sanjiu Medical & Pharmaceutical Chinese Medicine

Controversies

Controversies tied to this brand in public sources. A listing is not a finding of fault.

Back to profile1 entries

  1. 2015

    CR Sanjiu Subsidiary Recalls Shuxuening Injection After Sampling Failure, Suspends Production and Sales

    Securities Times reported that a sampling test on February 17, 2015 found two batches of China Resources Gaoke's Shuxuening Injection to be substandard. The company recalled the relevant batches and proactively expanded the recall, suspended production and sales of the product, and carried out risk assessment and rectification. The company said at the time that it had not received reports of serious adverse reactions. Progress: The company's announcement confirmed the recall and suspension of production and sales. Entities involved: Beijing China Resources Gaoke Natural Medicine Co., Ltd. and China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. Scope: An incident related to CR Sanjiu's traditional Chinese medicine business, limited to the subsidiary's Shuxuening product.

    Source